search
Back to results

Addition of Homeopathy in Patients With Resistant Arterial Hypertension

Primary Purpose

Hypertension, Resistant to Conventional Therapy

Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
Homeopathy
Placebo
Sponsored by
Macmillan Research Group UK
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension, Resistant to Conventional Therapy focused on measuring Resistant hypertension, Homeopathy, Blood pressure, Ambulatory blood pressure monitoring

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients older than 18 years with resistant arterial hypertension.
  • Office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite being treated with at least 3 antihypertensive drugs, including a diuretic.
  • Patients with diabetes or chronic kidney disease (defined as serum creatinine >133 μmol/L or proteinuria >300 mg/day) if the office BP was >130/80 mm Hg.

Exclusion Criteria:

  • Severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg) who needed an immediate adjustment of treatment,
  • Renal insufficiency with serum creatinine >180 μmol/L or glomerular filtration rate <40 mL/min calculated by the Modification of Diet in Renal Disease formula,15 hyperkalemia >5.4 mmol/L, hyponatremia <130 mmol/L, and porphyria;
  • Pregnant or lactating women or women of fertile age not using effective contraception;
  • Patients with known prior hypersensitivity to the drug Verospiron (spironolactone; Richter Gedeon Ltd) or who are currently using any aldosterone antagonist.

Sites / Locations

  • NMP Medical Research Institute
  • NMP Medical Research Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Homeopathy

Placebo

Arm Description

A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).

Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials

Outcomes

Primary Outcome Measures

Daytime systolic and diastolic pressure

Secondary Outcome Measures

24-hour systolic and diastolic BP

Full Information

First Posted
April 20, 2014
Last Updated
April 24, 2014
Sponsor
Macmillan Research Group UK
Collaborators
NMP Medical Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02124473
Brief Title
Addition of Homeopathy in Patients With Resistant Arterial Hypertension
Official Title
Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Homeopathy in Resistant Arterial Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Macmillan Research Group UK
Collaborators
NMP Medical Research Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Resistant hypertension (RHTN) is a common clinical problem faced by both primary care clinicians and specialists worldwide. Patients with RHTN have higher rates of cardiovascular events and mortality compared with patients with more easily controlled hypertension. In addition, RHTN is often complicated by metabolic abnormalities. Homeopathy, although widely used in hypertension, but no study has been taken to evaluate the impact on resistant hypertension. The aim of this trial was to evaluate individualized homeopathy on BP in patients with resistant hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Resistant to Conventional Therapy
Keywords
Resistant hypertension, Homeopathy, Blood pressure, Ambulatory blood pressure monitoring

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
79 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Homeopathy
Arm Type
Experimental
Arm Description
A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
Intervention Type
Other
Intervention Name(s)
Homeopathy
Intervention Type
Other
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Daytime systolic and diastolic pressure
Time Frame
Change from Baseline in Systolic and Diastolic Blood Pressure at 3 months
Secondary Outcome Measure Information:
Title
24-hour systolic and diastolic BP
Time Frame
Change from Baseline in 24-hour blood pressure at 3 months
Other Pre-specified Outcome Measures:
Title
Serum levels of sodium
Time Frame
Change from Baseline in Serum level of sodium at 3 months
Title
Serum levels of potassium
Time Frame
Change from Baseline in serum levels of potassium at 3months
Title
Serum levels of creatinine
Time Frame
Change from Baseline in Serum levels of creatinine at 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients older than 18 years with resistant arterial hypertension. Office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite being treated with at least 3 antihypertensive drugs, including a diuretic. Patients with diabetes or chronic kidney disease (defined as serum creatinine >133 μmol/L or proteinuria >300 mg/day) if the office BP was >130/80 mm Hg. Exclusion Criteria: Severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg) who needed an immediate adjustment of treatment, Renal insufficiency with serum creatinine >180 μmol/L or glomerular filtration rate <40 mL/min calculated by the Modification of Diet in Renal Disease formula,15 hyperkalemia >5.4 mmol/L, hyponatremia <130 mmol/L, and porphyria; Pregnant or lactating women or women of fertile age not using effective contraception; Patients with known prior hypersensitivity to the drug Verospiron (spironolactone; Richter Gedeon Ltd) or who are currently using any aldosterone antagonist.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vipin Sharma, BHMS
Organizational Affiliation
NMP Medical Research Institute, India
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Neha Sharma
Organizational Affiliation
Macmillan Research Group UK
Official's Role
Study Director
Facility Information:
Facility Name
NMP Medical Research Institute
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302019
Country
India
Facility Name
NMP Medical Research Institute
City
Jhunjhunu
State/Province
Rajasthan
Country
India

12. IPD Sharing Statement

Learn more about this trial

Addition of Homeopathy in Patients With Resistant Arterial Hypertension

We'll reach out to this number within 24 hrs